Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9152W HIGH $10.30
Volume
41.61 K
Value Traded
1.56 M
Short % Float
1.01%
Days to Cover
1.0
+8.33%Week
-23.03%1 Month
-16.43%3 Month
-72.14%6 Month
-99.67%5 Year
-99.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.90 M
EPS (TTM)
-32.52
P/E Ratio
-
Ent. Value
102.57 K
Total Shares
1.62 M
Float Shares
1.62 M
Insiders
0.10%
Institutions
6.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PPBT Catalyst Timeline
Dated clinical, regulatory and corporate events for Purple Biotech Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Purple Biotech Ltd.
516Total events
9Upcoming
138Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCIM1240Preclinical
Non-GLP toxicology study in NHPs validates CAPTN-3 masking strategy
head and neck squamous cell carcinoma, non-small cell lung cancer, bladder cancersource ↗
◆Poster PresentationIM1240Presentation
Poster presentation at EACR 2026 on IM1240 preclinical data
head and neck squamous cell carcinoma, non-small cell lung cancer, bladder cancersource ↗
▲Preclinical PoCIM1240Preclinical
New patient-derived tumor data demonstrated potent anti-tumor activity across all treatment-resistant samples
solid tumorssource ↗
▲Partnership / LicenseCorporate
Expanded collaboration with Converge Bio to apply generative AI to tri-specific antibody design
●Quarterly UpdateCorporate
Reported Q1 2026 financial results; cash position $6.4M, runway into 2027
▲Preclinical PoCIM1240Preclinical
New preclinical data for IM1240 showing anti-tumor activity in patient-derived tumor samples
multiple solid tumors (NSCLC, head and neck, bladder, triple-negative breast cancer)source ↗
▲Partnership / LicenseCorporate
AI collaboration with Converge Bio to accelerate tri-specific antibody platform
oncologysource ↗
●Reverse Stock SplitCorporate
ADS ratio change effective (1:10 reverse ADS split) to regain Nasdaq compliance
▲Preclinical PoCIM1240Preclinical
Completed non-human primate toxicology study for IM1240 demonstrating expanded therapeutic window
solid tumorssource ↗
▼Program DiscontinuationCM-24 and Nivolumab- Dose EscalationCorporate
CM24 development contingent on partnering; impairment recognized
pancreatic ductal adenocarcinomasource ↗
▼Program DiscontinuationNT219Corporate
NT219 development contingent on partnering; impairment recognized
squamous cell carcinoma of the head and necksource ↗
◆Quarterly UpdateCorporate
Extraordinary General Meeting of Shareholders to approve equity-based awards
▲Poster PresentationIM1240Presentation
Preclinical data for IM1240 presented at ESMO IO Congress 2025
solid tumorssource ↗
▲Poster PresentationIM1305Presentation
Preclinical data for IM1305 presented at ESMO IO Congress 2025
triple-negative breast cancersource ↗
▲Preclinical PoCIM1240Preclinical
Positive preclinical data presented at ESMO Immuno-Oncology Congress 2025 for IM1240
cancersource ↗
▲Preclinical PoCIM1305Preclinical
Positive preclinical data presented at ESMO Immuno-Oncology Congress 2025 for IM1305
cancersource ↗
▲Development Candidate NominationIM1305Preclinical
Initiated development of second CAPTN-3 tri-specific antibody targeting TROP2
solid tumorssource ↗
▲Manufacturing MilestoneIM1240CMC / Inspection
Manufacturing milestone achieved for IM1240
solid tumorssource ↗
▲Patent GrantedNT219IP / Competition
European Patent Office issues intention to grant patent covering NT219 combinations with immunotherapies or MEK inhibitors
cancersource ↗
▲Trial InitiationNT219Trial
Phase 2 study of NT219 in combination with cetuximab or pembrolizumab initiated in R/M SCCHN
squamous cell carcinoma of the head and neck (SCCHN)source ↗
▲Pre IND MeetingIM1240FDA Meeting
Pre-IND meeting with FDA provided clear roadmap for non-clinical and clinical development
solid tumorssource ↗
●Trial InitiationIM1305Trial
Initiate development of IM1305: capped-CD3xTROP2xNKG2A
solid tumorssource ↗
●Quarterly UpdateCorporate
Cash balance $10.5M as of September 10, 2025; cash runway into 1H 2027
▼Equity OfferingCorporate
Pricing of up to $18 million public offering ($6 million upfront plus up to $12 million from short-term warrants)
▲Preclinical PoCIM1240Preclinical
New data from Dr. Horowitz shows IM1240 induces cancer cell apoptosis in patient-derived HNSCC biopsies resistant to anti-PD1 therapy
head and neck squamous cell carcinomasource ↗
▲Preclinical PoCIM1305Preclinical
Encouraging in-vivo results for IM1305 demonstrating sustained tumor regression in TNBC mouse model
triple negative breast cancersource ↗
◆Trial InitiationCM-24 and Nivolumab- Dose EscalationTrial
Initiation of Phase 2b for CM24 in pancreatic cancer expected 2H25
Pancreatic Cancersource ↗
▲Trial InitiationNT219Trial
Initiation of Phase 2 study of NT219 in combination with pembrolizumab or cetuximab in R/M SCCHN
recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)source ↗
●Poster PresentationCAPTN-3Presentation
Poster presentation of CAPTN-3 preclinical data at EACR 2025
solid tumorssource ↗
▲Full ResultsCM-24 and Nivolumab- Dose EscalationClinical Data
Completed Phase 2 study of CM24 in combination with nivolumab and chemotherapy for PDAC
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Trial InitiationNT219Trial
Initiated Phase 2 study of NT219 in combination with cetuximab or pembrolizumab in R/M SCCHN
recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)source ↗
▲Patent GrantedNT219IP / Competition
US patent issued for NT219 in combination with EGFR antibodies
cancersource ↗
▲Partnership / LicenseCAPTN-3Corporate
Research collaboration with Icahn School of Medicine at Mount Sinai
cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How PPBT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | CM24 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 89%
Micro Cap(rank 585 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NT219 Small moleculeCompletedNCT04474470 | Solid Tumor, Adult | Phase 1 | COMPLETED | 52 | May 8, 2024 | ||||||
| CM-24 and Nivolumab- Dose Escalation Small moleculeCompletedNCT04731467 | Solid Tumor | Phase 1 | COMPLETED | 79 | Sep 30, 2024 | ||||||
| OE amlodipine Small moleculeMarketedNCT02979197 | Hypertension | Phase 3 | COMPLETED | 105 | Jul 21, 2017 | ||||||
| Over-encapsulated amlodipine Small moleculeMarketedNCT02172040 | Hypertension | Phase 3 | COMPLETED | 152 | Nov 19, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every PPBT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CM24 | pancreatic ductal adenocarcinoma (PDAC) | Phase 2 | 2025-08-06 | Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025Read More | Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKGRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PPBT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 % | 86.00 K | 17.71 K | -43.62% ( -13.71 K) |
PPBT Institutional Ownership Trends
PPBT Short Interest
Shares sold short, counted twice a month.
1.01%
Short % of Float
of tradable shares sold short
16.3K
Shares Sold Short
-9.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
23.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PPBT ranks across every disease it competes in
Competitive Position is a premium feature
See how PPBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPPBT News
-PPBT
Oct 29, 2026▲ +13.9%on this news
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
Purple Biotech announced that its abstract on IM1240 has been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium. The presentation will discuss IM1240's efficacy in treatment-resistant tumor models and its safety profile. The event is scheduled for November 20, 2026, in Barcelona, Spain.
Read more →-PPBT
Sep 2, 2026▲ +19.3%on this news
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
Purple Biotech Ltd. announced a U.S. Patent Notice of Allowance for its CAPTN-3 platform, which covers tri-specific antibody constructs. This patent enhances the company's intellectual property, allowing for more efficient development of multispecific antibodies targeting various cancers. CEO Gil Efron highlighted the importance of this allowance in evolving their therapeutic capabilities.
Read more →-PPBT
Aug 7, 2026Purple Biotech Reports Second Quarter 2026 Financial Results
Purple Biotech reported a net income of $0.4 million for the second quarter of 2026. The company holds $6.1 million in cash, which supports operations through mid-2027. Management plans to advance its lead candidate, IM1240, into clinical studies next year. Recent preclinical data highlighted the drug's improved safety and efficacy profile.
Read more →-PPBT
Jun 11, 2026▼ -48%on this news
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Purple Biotech presented promising preclinical data for IM1240 at EACR 2026, highlighting its anti-tumor efficacy in chemotherapy-resistant cancers. The study demonstrated improved pharmacokinetics and a favorable safety profile compared to non-capped variants. IM1240's mechanism involves inducing immune cell structures that enhance anti-tumor responses, supporting its advancement towards clinical trials in 2027.
Read more →-PPBT
May 15, 2026▲ +6.8%on this news· ran to -19% by day 3
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
Purple Biotech reported its Q1 2026 financial results, highlighting the promising anti-tumor activity of its tri-specific antibody IM1240. The company established a Scientific Advisory Board and expanded its collaboration with Converge Bio to enhance antibody development using AI. Despite increased operating expenses, the company maintains a solid cash position expected to last into 2027.
Read more →-PPBT
Apr 27, 2026Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Purple Biotech has announced promising preclinical data regarding its lead tri-specific antibody, IM1240, from the CAPTN-3 platform. This data, generated in collaboration with Dr. Amir Horowitz at the Icahn School of Medicine at Mount Sinai, showed that all seven tested patient-derived tumor samples responded positively to IM1240 treatment. Notably, the treatment enhanced anti-tumor activity and induced favorable immune responses in various cancer types, including resistant cases. The results suggest IM1240's potential as a significant therapeutic option for patients with difficult-to-treat cancers.
Read more →-PPBT
Apr 23, 2026▼ -8.1%on this newsshared move
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech has announced the formation of a Scientific Advisory Board (SAB) to support the development of its CAPTN-3 tri-specific antibody platform for immunotherapy. The SAB includes renowned experts in the fields of T cell and NK cell therapies, aimed at enhancing the efficacy and safety of anti-cancer treatments. This new advisory team will provide strategic guidance as Purple Biotech progresses toward clinical development, leveraging a unique approach in immunotherapy that targets tumor-associated antigens while engaging immune cells. The CAPTN-3 platform is designed to confine immune activation to the tumor microenvironment, which could improve therapeutic outcomes.
Read more →-PPBT
Mar 25, 2026Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform through the use of advanced generative AI. This partnership aims to leverage AI capabilities to improve the design and optimization of antibodies specifically for oncology applications. The collaboration seeks to accelerate discovery timelines, enhance the quality of drug candidates, and expand Purple Biotech's pipeline with high-quality therapeutics. The integration of AI technologies marks a significant step in Purple Biotech's strategy to lead in multi-specific antibody therapies.
Read more →-PPBT
Mar 19, 2026CORPORATE PRESENTATION March 2026 Advancing the next Generation of Immuno - oncology NASDAQ/TASE : PPBT 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking an
PPBT is advancing its lead program IM1240, a tri-specific antibody designed to target solid tumors, with clinical trials planned to begin in 2027. The CAPTN - 3 platform showcases improved safety and efficacy metrics, potentially addressing challenges faced by current T-cell engagers. The company is optimistic about ongoing partnerships related to its Phase 2 programs, CM24 and NT219, which show positive clinical data. Financially, PPBT is secure through key milestones, ensuring operations continue into 2027.
Read more →-PPBT
Mar 17, 2026Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
Purple Biotech Ltd. has successfully regained compliance with Nasdaq's minimum bid price requirement, confirming it can continue listing on the platform. The company achieved the minimum closing bid price for its American Depositary Shares (ADSs) of $1.00 or more over 10 consecutive business days. Purple Biotech is focused on its next-generation immunotherapy platform, particularly advancing its lead candidate IM1240 and further developing candidates IM1305 and CM24, which have shown promise in clinical trials.
Read more →-PPBT
Mar 13, 2026▲ +6.8%on this newsshared move
Purple Biotech Announces CEO Transition
Purple Biotech announced that CEO Gil Efron will step down in August 2026 due to health reasons but will remain involved in corporate development. The Board has begun the search for a new CEO while expressing confidence in the company's strategic direction and pipeline, particularly the CAPTN-3 platform. Efron has played a significant role in the company's transformation over the past eight years.
Read more →-PPBT
Mar 13, 2026▲ +6.8%on this newsshared move
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial
Purple Biotech reported its fourth quarter and full year 2025 financial results, emphasizing the prioritization of the CAPTN-3 platform's tri-specific antibodies IM1240 and IM1305. The company achieved important preclinical milestones, including positive data presented at the ESMO Immuno-Oncology Congress 2025. However, it also faced a substantial impairment loss of $20.5 million due to the reassessment of other developmental assets, impacting its overall financial performance for the year.
Read more →-PPBT
Feb 25, 2026Purple Biotech Announces Plan to Implement ADS ADS Will Begin Trading Reflecting the Ratio
Purple Biotech Ltd. has announced a change to its American Depositary Shares (ADS) ratio, effective from March 2, 2026. The ratio will change from one ADS representing 200 ordinary shares to one ADS representing 2,000 ordinary shares. This adjustment aims to help the company meet the $1.00 minimum bid price requirement for continued Nasdaq listing. While the change may enhance the liquidity of ADS trading, the company has cautioned that there is no assurance regarding the post-change trading price.
Read more →-PPBT
Jan 13, 2026CORPORATE PRESENTATION January 2026 Advancing the next Generation of Immuno - oncology NASDAQ/TASE : PPBT Certain statements in this presentation that are forward - looking and not statements of historical fact are forwa
The corporate presentation details PPBT's progress in advancing the CAPTN-3 platform for immuno-oncology. Noteworthy is the impending Phase 1 initiation of the tri-specific antibody IM1240 in H2 2026, and positive data from two Phase 2 clinical programs that present partnership opportunities. The presentation also emphasizes the platform's enhanced safety and efficacy for targeting solid tumors. However, challenges related to drug development timelines, regulatory approvals, and market uncertainties were highlighted.
Read more →-PPBT
Jan 7, 2026Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
Purple Biotech has announced the successful completion of a toxicology study for its tri-specific antibody, IM1240, showing an expanded therapeutic window. The study indicated that IM1240 can be dosed up to 300-fold higher than a non-capped comparator while demonstrating improved safety, particularly through reduced immune-related toxicity. The company plans to advance IM1240 toward first-in-human clinical trials, with regulatory submission expected in the second half of 2026. These findings suggest a promising future for IM1240 in immunotherapy applications against solid tumors.
Read more →-PPBT
Dec 11, 2025Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
Purple Biotech has reported promising preclinical results from its CAPTN-3 tri-specific antibody platform at the ESMO Immuno-Oncology Congress 2025. The data showcases two antibodies, IM1240 and IM1305, demonstrating significant anti-tumor activity across various solid tumors, including cases resistant to PD1 therapy. This platform unites multiple immunological mechanisms, indicating its potential broad applicability in cancer treatment. The findings highlight Purple Biotech's ongoing development efforts as it prepares for key milestones in 2026.
Read more →-PPBT
Dec 4, 2025▲ +8.2%on this news
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Purple Biotech will present new preclinical data on its CAPTN-3 tri-specific antibody platform at the ESMO-IO 2025 Annual Congress. The data highlights the platform's versatility and anti-tumor activity, particularly in treatment-resistant cancers. CEO Gil Efron expressed confidence in the platform's ability to overcome tumor evasion and drug resistance.
Read more →-PPBT
Nov 19, 2025NASDAQ/TASE: PPBT November 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -
Purple Biotech presented a corporate overview highlighting its pipeline of oncology products, including two promising candidates, CM24 and NT219. CM24 has demonstrated positive results in early-stage clinical trials aimed at personalized immunotherapy for cancer, while NT219 targets tumor resistance mechanisms. The company is strategically positioned to advance its first-in-class dual conditionally-activated therapies, with a significant cash balance providing development runway through early 2027. The potential impacts of current regulatory environments and market dynamics were also outlined as critical factors for future performance.
Read more →-PPBT
Nov 14, 2025Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
Purple Biotech reported its financial results for Q3 2025 and outlined key updates in its business operations. The company initiated the development of a second CAPTN-3 tri-specific antibody targeting TROP2 and achieved a manufacturing milestone for IM1240. Despite a cash position of $10.5 million that extends its runway into early 2027, Purple Biotech recorded a net loss of $1.3 million, an increase from the previous year's loss. The company continues to focus on toxicology studies and advancing its CAPTN-3 technology platform moving forward.
Read more →-PPBT
Oct 29, 2025▲ +81.8%on this news
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Purple Biotech has achieved a significant manufacturing milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform. This development validates the scalability of the platform and positions IM1240 for future clinical trials, with an IND submission expected in 2026. The antibody targets the 5T4 antigen and is designed to enhance anti-tumor immune responses while minimizing off-tumor activation.
Read more →About Purple Biotech Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next PPBT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime